Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (27297)	1/7/1999 10:56:00 AM
From: Machaon	Respond to of 32384

<< Bob, The vote on safety and efficacy was 14-0. >> That sounds great. If found it interesting that all patients that responded clinically to ONTAK also had improvements in their symptoms: ===> "Symptom improvement was reported by all patients identified as responders." Also, 80% of those that did not receive a clinical response had improvements in their symptoms: ===> "Symptomatic improvement was also reported in 80 percent of patients who did not achieve an objective clinical response." This waiting is reminiscent of the movie High Noon. We are all waiting for the train to come it. Will Frank Miller be on the train to shoot holes in the LGND stock, or will it contain an FDA approval? Good luck to LGND shareholders, Bob